CL2011003082A1 - Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa. - Google Patents

Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa.

Info

Publication number
CL2011003082A1
CL2011003082A1 CL2011003082A CL2011003082A CL2011003082A1 CL 2011003082 A1 CL2011003082 A1 CL 2011003082A1 CL 2011003082 A CL2011003082 A CL 2011003082A CL 2011003082 A CL2011003082 A CL 2011003082A CL 2011003082 A1 CL2011003082 A1 CL 2011003082A1
Authority
CL
Chile
Prior art keywords
triazolo
pyridine
treatment
jak2
compounds derived
Prior art date
Application number
CL2011003082A
Other languages
English (en)
Inventor
A Cury Matthew
J Dugan Benjamin
F Mesaros Eugen
D Dosey Bruce
E Gingrich Diane
L Milkiewicz Karen
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42985748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011003082(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of CL2011003082A1 publication Critical patent/CL2011003082A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compuestos derivados de n-fenil[1,2,4]triazolo[1,5-a]piridin-amina, moduladores de tirosina-cinasa como fak o jak; composición farmacéutica; y su uso para el tratamiento de una enfermedad hiperproliferativa, tal como cáncer.
CL2011003082A 2009-06-05 2011-12-05 Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa. CL2011003082A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18453309P 2009-06-05 2009-06-05
PCT/US2010/037363 WO2010141796A2 (en) 2009-06-05 2010-06-04 PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES

Publications (1)

Publication Number Publication Date
CL2011003082A1 true CL2011003082A1 (es) 2012-06-08

Family

ID=42985748

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011003082A CL2011003082A1 (es) 2009-06-05 2011-12-05 Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa.

Country Status (14)

Country Link
US (2) US8501936B2 (es)
EP (1) EP2438066A2 (es)
JP (1) JP5684245B2 (es)
KR (1) KR20120044966A (es)
CN (1) CN102459258B (es)
AU (1) AU2010254806C1 (es)
BR (1) BRPI1009637A2 (es)
CA (1) CA2763900A1 (es)
CL (1) CL2011003082A1 (es)
IL (1) IL216609A0 (es)
MX (1) MX2011012961A (es)
NZ (1) NZ597140A (es)
TW (1) TWI500614B (es)
WO (1) WO2010141796A2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110063A1 (es) * 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
BRPI0910021A2 (pt) 2008-06-20 2015-09-01 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinas em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
US9023851B2 (en) * 2010-08-27 2015-05-05 Merck Patent Gmbh Triazolopyrazine derivatives
JP6046633B2 (ja) * 2010-12-06 2016-12-21 セファロン、インク． １，２，４−トリアゾロ［１，５ａ］ピリジン誘導体を用いた慢性炎症の治療
JP6033230B2 (ja) * 2010-12-06 2016-11-30 セファロン、インク． 狼瘡の処置のためのヤーヌスキナーゼ２（ｊａｋ２）インヒビタ
DK2675794T3 (da) 2011-02-17 2019-05-06 Cancer Therapeutics Crc Pty Ltd Selektive fak-inhibitorer
WO2012110773A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors
EP2714703B1 (en) * 2011-05-31 2021-03-10 Newgen Therapeutics, Inc. Tricyclic inhibitors of poly(adp-ribose)polymerase
CN104185420B (zh) 2011-11-30 2017-06-09 埃默里大学 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
KR20130091464A (ko) * 2012-02-08 2013-08-19 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체
CN104114557B (zh) * 2012-02-21 2017-10-24 默克专利股份公司 作为syk酪氨酸激酶抑制剂和gcn2丝氨酸激酶抑制剂的8‑取代2‑氨基‑[1,2,4]三唑并[1,5‑a]吡嗪
WO2013131609A1 (en) * 2012-03-07 2013-09-12 Merck Patent Gmbh Triazolopyrazine derivatives
CN104379173A (zh) * 2012-06-22 2015-02-25 加拉帕戈斯股份有限公司 用于治疗炎症的氨基三唑并吡啶及其药物组合物
KR20150040845A (ko) * 2012-07-10 2015-04-15 바이엘 파마 악티엔게젤샤프트 치환된 트리아졸로피리딘을 제조하는 방법
KR20150038241A (ko) * 2012-07-27 2015-04-08 노파르티스 아게 Jak/stat 억제제에 대한 치료 반응의 예측
US20160123982A1 (en) 2013-02-04 2016-05-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
CA2922770A1 (en) * 2013-09-05 2015-03-12 F. Hoffmann-La Roche Ag Triazolopyridine compounds, compositions and methods of use thereof
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3265464A1 (en) * 2015-03-04 2018-01-10 F. Hoffmann-La Roche AG Triazolopyridine compounds and methods of use thereof
JP6978098B2 (ja) * 2016-07-26 2021-12-08 スーヂョウ ロングバイオテック ファーマシューティカルズ カンパニー リミテッドSuzhou Longbiotech Pharmaceuticals Co., Ltd. 選択的ｊａｋ阻害剤としての化合物、該化合物の塩類および治療への使用
CN107759587B (zh) * 2016-08-19 2021-01-26 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
EP3510030B1 (en) * 2016-09-06 2023-03-22 F. Hoffmann-La Roche AG 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
CN107880038B (zh) * 2016-09-30 2021-09-28 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
EA039344B1 (ru) * 2017-01-19 2022-01-17 Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд. Гетероциклическое соединение в качестве ингибитора jak и его соли и терапевтическое применение
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
US20210403462A1 (en) 2018-11-05 2021-12-30 Syngenta Participations Ag Pesticidally active azole-amide compounds
WO2020116662A1 (ja) 2018-12-06 2020-06-11 第一三共株式会社 シクロアルカン−１，３−ジアミン誘導体
EP3956330A4 (en) 2019-04-18 2023-01-18 The Johns Hopkins University SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND THEIR USE
CN111057059B (zh) * 2019-11-25 2022-04-26 广东省测试分析研究所（中国广州分析测试中心） 一种苯并二四氢吡咯类化合物或其药学上可接受的盐、及其制备方法和应用
JP2023525047A (ja) 2020-05-06 2023-06-14 エイジャックス セラピューティクス， インコーポレイテッド Ｊａｋ２阻害薬としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール
WO2023009708A1 (en) * 2021-07-29 2023-02-02 Ajax Therapeutics, Inc. Heteroaryloxy triazolo- and imidazo-azines as jak2 inhibitors
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492696A (en) * 1989-04-14 1996-02-20 The Government Of The United States Of America As Represented By The Secretary Of The Navy Controlled release microstructures
US5651976A (en) * 1993-06-17 1997-07-29 The United States Of America As Represented By The Secretary Of The Navy Controlled release of active agents using inorganic tubules
US5705191A (en) * 1995-08-18 1998-01-06 The United States Of America As Represented By The Secretary Of The Navy Sustained delivery of active compounds from tubules, with rational control
US6936215B1 (en) * 1996-08-27 2005-08-30 The United States Of America As Represented By The Secretary Of The Navy Processing methodology for the rational control of bilayer numbers leading to high efficiency production of lipid microtubules
PL190282B1 (pl) 1996-09-24 2005-11-30 Dow Agrosciences Llc Związki N-([1,2,4]triazoloazynylo)benzeno-i pirydynosulfonamidowe, zawierające je kompozycje herbicydowe, pochodne chlorku pirydyno-3-sulfonylu i pochodne 2-amino[1.2.4]triazolo[1.5-c]pirymidyny
US6013206A (en) * 1998-05-18 2000-01-11 The United States Of America As Represented By The Secretary Of The Navy Process for the formation of high aspect ratio lipid microtubules
US6401816B1 (en) * 1999-03-03 2002-06-11 The United States Of America As Represented By The Secretary Of The Navy Efficient method for subsurface treatments, including squeeze treatments
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
US6518222B2 (en) 2000-11-03 2003-02-11 Dow Agrosciences Llc N-([1,2,4] triazoloazinyl) thiophenesulfonamide compounds and their use as herbicides
PT1341769E (pt) 2000-12-15 2007-12-31 Vertex Pharma Inibidores de girase bacteriana e suas utilizações
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
US6693116B2 (en) 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
AU2003249477A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
US7125476B2 (en) * 2003-01-30 2006-10-24 The United States Of America As Represented By The Secretary Of The Navy Microwave-attenuating composite materials, methods for preparing the same, intermediates for preparing the same, devices containing the same, methods of preparing such a device, and methods of attenuating microwaves
WO2005009348A2 (en) 2003-06-25 2005-02-03 Ariad Pharmaceuticals, Inc. Substituted purine derivatives
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US7491263B2 (en) * 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
CA2576297C (en) 2004-08-12 2011-01-25 Pfizer Inc. Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
BRPI0516819A (pt) 2004-10-07 2008-09-23 Warner Lambert Co derivados de triazolopiridina e agentes antibacterianos
US7400490B2 (en) * 2005-01-25 2008-07-15 Naturalnano Research, Inc. Ultracapacitors comprised of mineral microtubules
TW200638882A (en) 2005-02-04 2006-11-16 Senomyx Inc Molecules comprising linked organic moieties as flavor modifiers for comestible compositions
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
EP1832629B1 (en) * 2006-03-10 2016-03-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Corrosion inhibiting pigment comprising nanoreservoirs of corrosion inhibitor
CA2650976A1 (en) 2006-05-02 2007-11-15 Pfizer Products Inc. Bicyclic heteroaryl compounds as pde10 inhibitors
EP2029605A1 (en) * 2006-06-06 2009-03-04 Schering Corporation Imidazopyrazines as protein kinase inhibitors
WO2008001182A1 (en) 2006-06-26 2008-01-03 Pfizer Products Inc. Tricyclic heteroaryl compounds as pde10 inhibitors
WO2008006540A1 (en) 2006-07-12 2008-01-17 Syngenta Participations Ag Triazolopyridine derivatives as herbicides
WO2008025821A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
WO2008045393A2 (en) 2006-10-11 2008-04-17 Amgen Inc. Imidazo- and triazolo-pyridine compounds and methods of use therof
ATE495743T1 (de) 2006-12-01 2011-02-15 Galapagos Nv Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
US20080248201A1 (en) * 2007-04-06 2008-10-09 Naturalnano Research, Inc. Polymeric coatings including nanoparticle filler
NZ580394A (en) 2007-04-10 2011-10-28 Lundbeck & Co As H Heteroaryl amide analogues as p2x7 antagonists
ATE540037T1 (de) 2007-04-16 2012-01-15 Leo Pharma As Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten
EA016679B1 (ru) 2007-04-18 2012-06-29 Пфайзер Продактс Инк. Сульфониламидные производные для лечения аномального роста клеток
AR066845A1 (es) 2007-06-05 2009-09-16 Takeda Pharmaceutical Derivados de triazolopiridina e imidazopiridina una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento del cancer
US8053574B2 (en) 2007-07-18 2011-11-08 Novartis Ag Organic compounds
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
AU2008287421A1 (en) 2007-08-10 2009-02-19 Glaxosmithkline Llc Nitrogen containing bicyclic chemical entities for treating viral infections
WO2009027736A2 (en) 2007-08-27 2009-03-05 Astrazeneca Ab 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
EP2184285B1 (en) 2007-08-29 2015-11-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2009027283A1 (en) 2007-08-31 2009-03-05 Merck Serono S.A. Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2009048474A1 (en) 2007-10-12 2009-04-16 Pharmacopeia, Inc. 2,7,9-substituted purinone derivatives for immunosuppression
WO2009068482A1 (en) 2007-11-27 2009-06-04 Cellzome Limited Amino triazoles as pi3k inhibitors
WO2009136663A1 (en) 2008-05-08 2009-11-12 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
BRPI0910021A2 (pt) 2008-06-20 2015-09-01 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinas em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
PE20110063A1 (es) 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
WO2010007100A1 (en) 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010184A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
AR073010A1 (es) * 2008-08-12 2010-10-06 Takeda Pharmaceutical Compuesto amida con actividad agonista del gpr52
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
JP2010070503A (ja) 2008-09-19 2010-04-02 Daiichi Sankyo Co Ltd 抗真菌作用２−アミノトリアゾロピリジン誘導体
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
AU2009328752B2 (en) 2008-12-19 2015-07-16 Leo Pharma A/S Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
EP2396324A1 (en) * 2009-02-13 2011-12-21 Fovea Pharmaceuticals Ý1, 2, 4¨triazolo ý1, 5 -a¨pyridines as kinase inhibitors
CA2784769A1 (en) * 2010-01-15 2011-07-21 Janssen Pharmaceuticals, Inc. Novel substituted triazole derivatives as gamma secretase modulators

Also Published As

Publication number Publication date
KR20120044966A (ko) 2012-05-08
MX2011012961A (es) 2012-01-30
IL216609A0 (en) 2012-02-29
TW201100421A (en) 2011-01-01
JP5684245B2 (ja) 2015-03-11
JP2012528886A (ja) 2012-11-15
CN102459258A (zh) 2012-05-16
CA2763900A1 (en) 2010-12-09
US8633173B2 (en) 2014-01-21
AU2010254806B2 (en) 2016-02-04
US20130296312A1 (en) 2013-11-07
US8501936B2 (en) 2013-08-06
BRPI1009637A2 (pt) 2019-04-30
WO2010141796A3 (en) 2012-02-16
TWI500614B (zh) 2015-09-21
AU2010254806A1 (en) 2012-01-19
US20100311693A1 (en) 2010-12-09
WO2010141796A2 (en) 2010-12-09
EP2438066A2 (en) 2012-04-11
NZ597140A (en) 2014-01-31
CN102459258B (zh) 2015-11-25
AU2010254806C1 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
CL2011003082A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa.
ECSP109934A (es) Compuesto - 946
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
NI201000004A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
ECSP12011855A (es) COMPUESTOS DE pIrrolo[2,3-d]pIrimidinA
UY30559A1 (es) Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones
CL2008002243A1 (es) Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CU20110129A7 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
BRPI0915084B8 (pt) composto, e, composição farmacêutica
ECSP11011181A (es) Compuestos orgánicos
CL2008000946A1 (es) Compuestos derivados de pirrolopirimidina, inhibidores de cianasa jak3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de rechazo de transplantes, enfermedades autoinmun
UY30759A1 (es) Compuestos quimicos
ECSP11010904A (es) Compuestos de pirrolo[2,3-d]pirimidina
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
CL2011000973A1 (es) Compuestos derivados de pirazolo [1,5-a]pirimidina3-cabroxamida; composicion farmaceutica que los comprende, y uso para tratar o disminuir la gravedad de una enfermedad o condicion que responde a la inhibicion de la actividad de una jak quinasa.
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
CO6541643A2 (es) Derivados de imidazopirina como inhibidores de jak
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
UY29685A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen.
ECSP10010389A (es) Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa
CL2009000949A1 (es) Compuestos derivados de 1,2,3,5-tetrahidro-indolizina, 6,7,8,9-tetrahidro-4h-quinolizina sustituidos, inhibidores de la actividad de cinasa de mek; su composicion farmaceutica; su uso para el tratamiento de enfermedades hiperproliferativas, tal como cancer e inflamaciones.
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.
CL2009001112A1 (es) Compuestos derivados de cinolin-3-carboxamida, inhibidores de la quinasa csf-1r; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CU20100005A7 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas